Drug Trial Radar · NCT07933692
Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
432
Planned (sponsor's estimate)
Start
Oct 1, 2021
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Shandong Provincial HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Dongying People's Hospital; Zibo Central Hospital; Heze Municipal Hospital; Shengli Oilfield Hospital; Liaocheng People's Hospital; Tengzhou Central People's Hospital; Shandong Province Third hospital; Zaozhuang Municipal Hospital
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter randomized controlled trial evaluates the effect of edaravone dexborneol on blood-brain barrier repair in patients with acute anterior circulation large artery atherosclerotic ischemic stroke within 48 hours of onset. Patients are randomized 1:1 to receive either edaravone dexborneol (30mg/7.5mg BID IV) or edaravone (30mg BID IV) for 9±2 days, in addition to standard stroke treatment. The primary outcome is the change in blood-brain barrier permeability (Ktrans) measured by DCE-MRI. Secondary outcomes include neurological function scores, serum biomarkers, and safety events.
Conditions
- Acute Ischemic Stroke
Interventions
EdaravoneDrug
Edaravone 30 mg administered by intravenous drip twice daily (BID) for 9±2 days, in addition to standard guideline-based treatment for acute ischemic stroke.
Edaravone DexborneolDrug
Edaravone dexborneol (30 mg/7.5 mg) administered by intravenous drip twice daily (BID) for 9±2 days, in addition to standard guideline-based treatment for acute ischemic stroke.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Ktrans (blood-brain barrier permeability) measured by DCE-MRITime frame: From baseline (24-48 hours after stroke onset) to day 9±2 after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.